Related Experiment Video
Updated: Apr 26, 2026
04:09
Minimal Invasive Resection of Large Retrosternal Thyroid Goiter
Published on: September 20, 2024
1.3K
Relapse following antithyroid drug therapy for Graves' hyperthyroidism
Peter Laurberg1, Anne Krejbjerg, Stine Linding Andersen
1aDepartment of Endocrinology, Aalborg University Hospital bDepartment of Clinical Medicine, Aalborg University, Aalborg, Denmark.
Current Opinion in Endocrinology, Diabetes, and Obesity
|August 12, 2014
Summary
Graves disease hyperthyroidism relapse is common after antithyroid drug (ATD) withdrawal. Identifying risk factors can help predict and manage relapse, potentially guiding longer ATD therapy for high-risk patients.
Area of Science:
- Endocrinology
- Immunology
- Pharmacology
Background:
- Graves' disease is a common cause of hyperthyroidism.
- Antithyroid drugs (ATDs) are a primary treatment, but relapse occurs in about 50% of patients after 1-2 years of therapy.
- Relapse of hyperthyroidism after ATD withdrawal is a significant clinical challenge.
Purpose of the Study:
- To review current knowledge on predicting relapse of hyperthyroidism after ATD withdrawal in Graves' disease.
- To explore strategies for reducing the risk of relapse.
Main Methods:
- Review of existing literature on risk factors for ATD withdrawal relapse in Graves' disease.
- Analysis of patient, disease, and treatment characteristics influencing relapse rates.
Main Results:
- Relapse risk after ATD withdrawal varies widely (10-90%) based on multiple factors.
- Key predictors include patient and disease characteristics, environmental factors, and ATD therapy duration.
- These risk factors should inform treatment decisions and discussions about therapy length.
Conclusions:
- Prolonged low-dose ATD therapy is a viable option for high-risk patients.
- Consideration for extended ATD therapy includes children, patients with active Graves' orbitopathy, and those with prior relapse preferring medical management over surgery or radioiodine.
Related Concept Videos
01:28Graves' Disease I: Introduction
15
Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence...
15
01:24Graves Disease II: Pathophysiology
15
Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor,...
15
01:25Hyperthyroidism I: Introduction
23
Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
23
01:27Hyperthyroidism II: Pathophysiology
18
Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH...
18
01:23Hypothyroidism II: Pathophysiology
15
Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...
15
01:20Synthesis and Regulation of Thyroid Hormones
7.0K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
7.0K